Petition Seeks Withdrawal of FDA Approval for rBGH

Scientists and others objecting to the use of recombinant bovine growth hormone (rBGH) to stimulate milk production in dairy cows have reportedly resubmitted a petition to the Food and Drug Administration (FDA) challenging the new animal drug application approval for an rBGH drug. FDA apparently failed to respond to the original petition, filed in 2007. The petition also requests that dairy products made from cows treated with rBGH be labeled with a health-hazard warning.

The petitioners include Samuel Epstein, chair of the Cancer Prevention Coalition; Ronnie Cummins, national director, Organic Consumers Association; Arpad Pusztai, a consultant biologist from Scotland; and Jeffrey Smith, executive director, Institute for Responsible Technology. They claim that rBGH milk poses major cancer and other risks to the U.S. population and that the drug has toxic effects on cows. See World-Wire.com, January 15, 2010.